Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascendis Pharma ( (ASND) ) just unveiled an announcement.
On October 8, 2025, Ascendis Pharma announced the submission of a Marketing Authorisation Application to the European Medicines Agency for TransCon CNP, a treatment for children with achondroplasia. This investigational prodrug aims to provide continuous inhibition of the FGFR3 pathway, potentially improving the quality of life for individuals with this rare genetic condition.
The most recent analyst rating on (ASND) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Ascendis Pharma stock, see the ASND Stock Forecast page.
Spark’s Take on ASND Stock
According to Spark, TipRanks’ AI Analyst, ASND is a Neutral.
Ascendis Pharma’s stock score is driven by strong earnings call highlights and positive technical indicators. However, financial performance and valuation concerns due to ongoing losses and reliance on debt financing weigh down the overall score.
To see Spark’s full report on ASND stock, click here.
More about Ascendis Pharma
Ascendis Pharma A/S is a biopharmaceutical company based in Denmark, specializing in the development of innovative therapies for rare diseases. The company focuses on creating prodrugs designed to improve patient outcomes through its proprietary TransCon technology platform.
Average Trading Volume: 468,150
Technical Sentiment Signal: Buy
Current Market Cap: $12.77B
For a thorough assessment of ASND stock, go to TipRanks’ Stock Analysis page.